Sutong Zhan
机构：Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University
发表论文 4 篇 · 总被引 30 次 · h-index 3
代表论文
- LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer (2024 · Journal for ImmunoTherapy of Cancer · 被引 14)
- MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC (2024 · Journal of Experimental & Clinical Cancer Research · 被引 10)
- Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer (2024 · Journal of Biomedical Research · 被引 6)
- [Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance]. (2026 · PubMed)